Category:

E.W. Scripps (SSP) – Hoping To Get A Nice Bounce

Posted on by cpereira@noblefcm.com


Wednesday, April 24, 2024

The E.W. Scripps Company (NASDAQ: SSP) is a diversified media company focused on creating a better-informed world. As one of the nation’s largest local TV broadcasters, Scripps serves communities with quality, objective local journalism and operates a portfolio of 61 stations in 41 markets. The Scripps Networks reach nearly every American through the national news outlets Court TV and Newsy and popular entertainment brands ION, Bounce, Defy TV, Grit, ION Mystery, Laff and TrueReal. Scripps is the nation’s largest holder of broadcast spectrum. Scripps runs an award-winning investigative reporting newsroom in Washington, D.C., and is the longtime steward of the Scripps National Spelling Bee. Founded in 1878, Scripps has held for decades to the motto, “Give light and the people will find their own way.”

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Potential Bounce TV sale. The company appears to be currently shopping its Over The Air (OTA) network Bounce TV, a network geared towards African American audiences. The sale of the Network, which would be viewed favorably, could take some of the pressure off of the company’s high debt leverage. Notably, CEO Adam Symson indicated that a deal could take place in the second or third quarter of this year. 

Strategic interest? There are a number of networks and programming companies that are focused on the attractive African American audience and could be strategic buyers for Bounce. We estimate that Bounce has shown attractive growth over the past several years, doubling in revenue since it purchased the network in 2017 to over $150 million in revenue in 2023. We estimate a potential selling price could be between $165 million to $225 million, or 1.1 to 1.5 times revenues.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

New Home Sales Rebound: A Boost for Small Caps and Economic Outlook

Posted on by slightbourne@noblecapitalmarkets.com

In the realm of economic indicators, few metrics capture the pulse of consumer sentiment and economic vitality quite like new home sales. The recent surge in new home sales in the United States, hitting a six-month high in March, is a beacon of hope amidst a backdrop of economic uncertainties. This uptick not only signifies resilience in the housing sector but also holds implications for small-cap investors and the broader macroeconomic landscape.

The Commerce Department’s latest report delivered a bullish narrative, showcasing an impressive 8.8% increase in new home sales, with a seasonally adjusted annual rate soaring to 693,000 units. This surge, attributed partly to the persistent shortage of previously owned homes on the market, underscores the robust demand for housing despite challenges such as escalating mortgage rates.

For small-cap investors, this uptick in new home sales is more than just a statistical blip—it’s a promising indicator of consumer confidence and economic buoyancy. Strong housing demand typically translates into a flurry of economic activity, benefiting small-cap companies operating in sectors ranging from home construction and building materials to home improvement and real estate services.

However, amid the celebratory numbers lies a cautionary tale. The accompanying rise in the median house price, coupled with the upward trajectory of mortgage rates, paints a nuanced picture. While higher home prices can fuel revenues for homebuilders and related industries, concerns about affordability may cast a shadow on overall housing market growth, impacting small caps tethered to this sector.

Zooming out to the macroeconomic panorama, the implications of these housing market dynamics are far-reaching. A robust housing sector is not just about building and selling homes; it’s a linchpin of economic stability, contributing significantly to GDP growth, job creation, and wealth accumulation.

Economists and savvy investors are keeping a keen eye on how these developments unfold in the coming months. The recent uptick in mortgage rates, coupled with a slight dip in mortgage applications, hints at potential headwinds for new home sales. This cautious sentiment underscores the delicate dance between market exuberance and economic prudence.

Regional nuances in new home sales add depth to the narrative. While all four U.S. regions experienced increases in new home sales, sentiments among single-family homebuilders remain cautious. Buyers, in turn, are treading carefully, weighing the impact of rising interest rates on their purchasing power.

For small-cap aficionados navigating this dynamic terrain, a balanced approach is the name of the game. While opportunities may abound in sectors riding the housing market wave, strategic risk management and diversified portfolios are non-negotiables in today’s evolving economic landscape.

In summary, the resurgence in new home sales injects a dose of optimism into the market narrative. However, prudence tempered with opportunism will be the guiding ethos for investors eyeing the small-cap space amid shifting economic tides.

Release – FAT Brands Inc. Announces Second Quarter Cash Dividend on Class A Common Stock and Class B Common Stock

Posted on by aweinsoff@channelchek.com

Research News and Market Data on FAT

04/23/2024

Download(opens in new window)

LOS ANGELES, April 23, 2024 (GLOBE NEWSWIRE) — FAT (Fresh. Authentic. Tasty.) Brands Inc. (NASDAQ: FAT), a leading global franchising company and parent company of iconic brands including Round Table Pizza, Fatburger, Marble Slab Creamery, Johnny Rockets, Twin Peaks, Fazoli’s, Smokey Bones and 11 other restaurant concepts, announced today that its Board of Directors has declared the Company’s fiscal 2024 second quarter cash dividend of $0.14 per share on each outstanding share of Class A common stock and Class B common stock. The dividend is payable on May 31, 2024 to holders of record of Class A common stock and Class B common stock as of the close of business on May 15, 2024.

The declaration and payment of future dividends, as well as the amounts thereof, are subject to the discretion of the Company’s Board of Directors. The amount and size of any future dividends will depend upon the Company’s future results of operations, financial condition, capital levels, cash requirements and other factors. There can be no assurance that the Company will declare and pay dividends in future periods.

About FAT (Fresh. Authentic. Tasty.) Brands

FAT Brands Inc. (NASDAQ: FAT) (the Company) is a leading global franchising company that strategically acquires, markets and develops quick service, fast casual and casual dining restaurant concepts around the world. The Company currently owns eighteen restaurant brands: Round Table Pizza, Fatburger, Marble Slab Creamery, Johnny Rockets, Fazoli’s, Twin Peaks, Smokey Bones, Great American Cookies, Hot Dog on a Stick, Buffalo’s Cafe & Express, Hurricane Grill & Wings, Pretzelmaker, Elevation Burger, Native Grill & Wings, Yalla Mediterranean, Ponderosa and Bonanza Steakhouses and franchises and owns over 2,300 units worldwide. For more information, please visit www.fatbrands.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to significant business, economic and competitive risks, uncertainties and contingencies, many of which are difficult to predict and beyond our control, which could cause our actual results to differ materially from the results expressed or implied in such forward-looking statements. We refer you to the documents we file from time to time with the Securities and Exchange Commission, such as our reports on Form 10-K, Form 10-Q and Form 8-K, for a discussion of these risks, uncertainties and contingencies. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this press release.

Investor Relations:
ICR
Michelle Michalski
IR-FATBrands@icrinc.com
646-277-1224

Media Relations:
FAT Brands Inc.
Erin Mandzik
emandzik@fatbrands.com
860 -212 -6509

Release – MAIA Biotechnology Announces $1.00 Million Private Placement

Posted on by aweinsoff@channelchek.com

Research News and Market Data on MAIA

April 23, 2024 8:51am EDT

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share, in a private placement to accredited investors and certain Company directors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.26 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed (subject to customary adjustments as set forth in the warrants). The warrants are exercisable commencing six months following issuance and have a term of five years from the initial exercise date. The securities being sold to the Company directors participating in the offering are being issued pursuant to the Company’s 2021 Equity Incentive Plan. The private placement is expected to close on or about April 25, 2024, subject to the satisfaction of customary closing conditions.

The gross proceeds from the offering are expected to be approximately $1.00 million, prior to offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for to fund research and development activities, such as to fund the first third of the pivotal accelerated approval Part C of the THIO-101 trial in non-small cell lung cancer (NSCLC).

The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240423249584/en/

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Source: MAIA Biotechnology, Inc.

Released April 23, 2024

Release – PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

Posted on by aweinsoff@channelchek.com

Research News and Market Data on PDSB

Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial

PRINCETON, N.J., April 23, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced a Key Opinion Leader (“KOL”) Event to discuss positive, updated data from its VERSATILE-002 Phase 2 clinical trial with Versamune® HPV in combination with KEYTRUDA® (pembrolizumab) (NCT04260126) and next steps for Versamune® HPV and PDS01ADC. The new data cut-off from VERSATILE-002 clinical trial remains consistent with the update provided by PDS Biotech in October of 2023.

The KOL event will take place on Wednesday, May 8, 2024, at 1:30 pm ET and panel participants will include:

  • Dr. Jared Weiss, M.D., Section Chief of Thoracic and Head/Neck Oncology, Professor of Medicine at University of North Carolina, and Principal Investigator of the VERSATILE-002 clinical trial who will present and discuss the trial results
  • Dr. Robert Haddad, M.D., Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute who will discuss the unmet need in HPV-positive head and neck squamous cell cancer (“HNSCC”)

The VERSATILE-002 trial is evaluating Versamune® HPV (formerly PDS0101) in combination with the immune checkpoint inhibitor (“ICI”) pembrolizumab in patients with unresectable, recurrent, or metastatic HPV16-positive HNSCC. The topline results to be discussed at the upcoming event are based on analysis of the most recent data cut-off.

“Approximately 20% of HPV-related patients with HNSCC will develop recurrent, incurable disease,” said Dr. Weiss. “HPV-related HNSCC that is recurrent or metastatic is a devastating, difficult-to-treat cancer, and a majority of patients do not respond to current treatments, and therefore have a relatively short survival. We believe that the data warrant further investigation in a randomized controlled clinical trial, and we are hopeful about the potential that the unique combination including Versamune® HPV and the IL-12 fused antibody drug conjugate PDS01ADC may represent in the treatment of HPV-related HNSCC.”

To register for the Key Opinion Leader event, click here.

About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines. The Company plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced head and neck squamous cell cancers (HNSCC). PDS Biotech’s lead program is a proprietary dual-acting combination of IL-12 fused antibody drug conjugate (ADC) PDS01ADC and T-cell activator Versamune® HPV in regimen with a standard-of-care immune checkpoint inhibitor. Proof-of-concept long-term data have shown positive survival results and tumor shrinkage with this combination and indicate favorable tolerability.

With a novel investigational “inside-outside” mechanism, the PDS01ADC and Versamune® HPV immunotherapy has shown compelling results with potential to successfully disrupt a tumor’s inside defenses, while also generating potent, targeted killer T-cells to attack the tumor from the outside. Robust data from more than 350 patients, as well as ongoing clinical trials across multiple tumor types and standard treatment regimens, have validated both platforms and point to potential broad utility.

Our Infectimune® based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses, including long-lasting memory T-cell responses in pre-clinical studies to date. For more information, please visit www.pdsbiotech.com.

Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS01ADC, PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS01ADC, PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. 

Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation.

Keytruda® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, N.J., USA.

Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:
Gina Mangiaracina
6 Degrees
Phone +1 (917) 797-7904
Email: gmangiaracina@6degreespr.com

Release – V2X to Announce First Quarter 2024 Financial Results

Posted on by aweinsoff@channelchek.com

Research News and Market Data on VVX

April 23, 2024

DOWNLOAD(OPENS IN NEW WINDOW)

MCLEAN, Va., April 23, 2024 /PRNewswire/ — V2X, Inc., (NYSE: VVX), a leading provider of global mission solutions, will report first quarter 2024 financial results on Tuesday, May 7, 2024, before market open. Senior management will conduct a conference call at 8:00 a.m. ET that same day.

U.S.-based participants may dial in to the conference call at 877-407-3982, while international participants may dial 201-493-6780. A live webcast of the conference call as well as an accompanying slide presentation will be available at https://app.webinar.net/24war3pJ8n7 and on the Investors section of the V2X website at https://gov2x.com/.

A replay of the conference call will be posted on the V2X website shortly after completion of the call and will be available for one year. A telephonic replay will also be available through May 21, 2024, at 844-512-2921 (domestic) or 412-317-6671 (international) with passcode 13745566.  

About V2X
V2X builds smart solutions designed to integrate physical and digital infrastructure – by aligning people, actions, and outputs. Formed by the merger of Vectrus and Vertex, we bring a combined 120 years of successful mission support. Our lifecycle solutions improve security, streamline logistics, and enhance readiness.

The Company delivers a comprehensive suite of integrated solutions across the operations and logistics, aerospace, training, and technology markets to national security, defense, civilian and international clients. Our global team of approximately 16,000 employees brings innovation to every point in the mission lifecycle, from preparation to operations, to sustainment, as it tackles the most complex challenges with agility, grit, and dedication.

Investor Contact 
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

Media Contact 
Angelica Spanos Deoudes
Director, Corporate Communications
Angelica.Deoudes@goV2X.com
571-338-5195

View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-to-announce-first-quarter-2024-financial-results-302123930.html

SOURCE V2X, Inc.

Release – Bowlero To Report Third Quarter 2024 Financial Results On May 6, 2024

Posted on by aweinsoff@channelchek.com

Research News and Market Data on BOWL

04/22/2024

RICHMOND, Va.–(BUSINESS WIRE)– Bowlero Corp. (NYSE: BOWL) (“Bowlero” or the “Company”), one of the world’s premier operators of location-based entertainment, will report financial results for the third quarter of fiscal 2024 on Monday, May 6, 2024, before the U.S. stock market opens. Management will discuss the results via webcast at 10:00 AM ET on the same day.

The live webcast, replay, and results presentation will be available in the Events & Presentations section of the Bowlero Investor Relations website at https://ir.bowlerocorp.com/.

About Bowlero Corp.

Bowlero Corporation is one of the world’s premier operators of location-based entertainment. With approximately 350 locations across North America, the Company serves more than 40 million guest visits annually through a family of brands that include Lucky Strike, Bowlero and AMF. In 2019, Bowlero acquired the Professional Bowlers Association, the major league of bowling and a growing media property that boasts millions of fans around the globe. For more information on Bowlero, please visit BowleroCorp.com.

IRSupport@BowleroCorp.com

Source: Bowlero Corp

Release – The GEO Group Announces Date for First Quarter 2024 Earnings Release and Conference Call

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GEO

April 22, 2024

PDF Version

  • Earnings Release Scheduled for Tuesday, May 7, 2024 Before the Market Opens
  • Conference Call Scheduled for Tuesday, May 7, 2024 at 11:00 AM (Eastern Time)

BOCA RATON, Fla.–(BUSINESS WIRE)–Apr. 22, 2024– The GEO Group, Inc. (NYSE:GEO) (“GEO”) will release its first quarter 2024 financial results on Tuesday, May 7, 2024 before the market opens. GEO has scheduled a conference call and simultaneous webcast for 11:00 AM (Eastern Time) on Tuesday, May 7, 2024.

Hosting the call for GEO will be George C. Zoley, Executive Chairman of the Board, Brian R. Evans, Chief Executive Officer, Shayn March, Acting Chief Financial Officer, Wayne Calabrese, President and Chief Operating Officer, and James Black, President, GEO Secure Services.

To participate in the teleconference, please contact one of the following numbers 5 minutes prior to the scheduled start time:

1-877-250-1553 (U.S.)
1-412-542-4145 (International)

In addition, a live audio webcast of the conference call may be accessed on the Webcasts section of GEO’s investor relations home page at investors.geogroup.com. A webcast replay will remain available on the website for one year.

A telephonic replay will also be available through May 14, 2024. The replay numbers are 1-877-344-7529 (U.S.) and 1-412-317-0088 (International). The passcode for the telephonic replay is 2879740. If you have any questions, please contact GEO at 1-866-301-4436.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240422631871/en/

Pablo E. Paez 1-866-301-4436
Executive Vice President, Corporate Relations

Source: The GEO Group, Inc.

Mining Titans Merge to Unleash Major Gold Discovery in Guiana Shield

Posted on by slightbourne@noblecapitalmarkets.com

G Mining Ventures (GMIN) is supercharging its growth strategy with the $875 million acquisition of junior explorer Reunion Gold and its massive Oko West gold project in Guyana. This transformative transaction instantly vaults GMIN into the elite ranks of premier mid-tier producers and showcases the huge rewards awaiting those who can execute on major discoveries.

Oko West already boasts an eye-popping 4.3 million ounces of indicated gold resources grading a robust 2.05 g/t. On top of that, it hosts another 1.6 million ounces of inferred resources at 2.59 g/t – over 1 million of those ounces are high-grade underground at 3.12 g/t. With this incredible size and scale, Oko West has all the hallmarks of a monster gold deposit ideally suited for a large-scale open-pit and underground mining operation.

Under the deal terms, Reunion shareholders receive 0.285 GMIN shares for each share held – representing about C$0.65 per share, a 29% premium. They also gain upside through an 80% stake in a spin-out vehicle holding Reunion’s other assets, funded with $15 million from GMIN.

For existing GMIN investors, Oko West provides a powerful second operational asset to go alongside the company’s near-term cash flow generator, the Tocantinzinho gold mine in Brazil on-track for late 2024 production. GMIN shrewdly raised $50 million in upfront equity financing from key backers La Mancha and Franco-Nevada to help fund Oko West, minimizing future shareholder dilution.

The lofty valuation GMIN paid underscores the premium attached to large, high-margin gold deposits in elite mining jurisdictions like the prolific Guiana Shield of South America. With exceptional projects of this caliber becoming extremely rare, an M&A frenzy is brewing as established producers race to replenish their ravaged reserve pipelines before valuations escalate further.

Soaring gold prices, tight supply, and escalating costs have heightened the appeal of de-risked, economically-resilient projects like Oko West already advanced to later stages. Few explorers can match GMIN’s powerful combination of a quality anchor asset generating cash flows, accomplished construction team with regional experience, and robust financial warchest to help crystallize Oko West’s full value.

A key advantage is GMIN’s in-house construction arm G Mining Services, which boasts extensive Guiana Shield expertise including delivering Newmont’s Merian mine ahead of schedule and under budget. This unmatched skill set is invaluable for safely navigating the complexities of developing a large, remote project like Oko West.

In addition to acquiring Oko West, GMIN gains exposure to new regional discoveries through Reunion’s spin-out company. This junior exploration vehicle is led by Reunion’s proven team and backed by a $15 million treasury to pursue the next big find across the underexplored Guiana Shield which continues delivering large, high-quality gold deposits.

The GMIN-Reunion merger showcases an emerging class of ambitious mid-tier producers diligently building diversified portfolios of long-life, high-margin assets across the Americas’ premiere mining districts. Through aggressive yet disciplined M&A of compelling discoveries demonstrating robust economics, GMIN aims to establish itself as a preeminent regional consolidator and operators.

With dwindling reserve inventories plaguing the sector, securing high-quality acquisitions in choice jurisdictions has become a strategic imperative for all but the most senior gold producers. Prolific belts like the Guiana Shield are rife with consolidation opportunities for well-capitalized counterparts able to fund and maximize development of world-class discoveries trapped within explorers’ portfolios.

Transformative deals like GMIN’s capture the upside of combining quality exploration assets with complementary construction capabilities under a single corporate engine optimized for growth. By uniting prospective resources with seasoned mine builders and operators, new mid-tiers are creating compelling vehicles to power the next big commodities M&A cycle.

In the perpetual hunt to replace dwindling reserves, the limited availability of sizable, high-grade resources in stable jurisdictions opens the pocketbooks of acquisitive producers. Projects like Oko West that flaunt elite size, grade and metallurgy across investment-friendly locales simply become irresistible targets for bigger fish further up the food chain.

GMIN’s Reunion acquisition stands as a tantalizing template for investors seeking the next emerging gold producer capable of rapidly ascending the value curve. Companies that stitch together prized asset bases could become the next sought-after prizes as industry consolidation kicks into overdrive.

Labrador Gold Corp. (NKOSF) – Labrador Gold Agrees to Sell its Flagship Project; Rating Lowered to Market Perform

Posted on by cpereira@noblefcm.com


Tuesday, April 23, 2024

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Agreement to sell the flagship Kingsway project. Labrador Gold agreed to sell its 100% interest in the Kingsway project to New Found Gold Corp. (TSXV: NFG) for C$20 million in NFG shares, including all property and mining rights. The number of shares received will be determined by dividing the purchase price by the closing price of NFG shares on the last trading day prior to the closing of the transaction.

Closing expected in the third quarter of 2024. The transaction is expected to close in the third quarter of 2024 and is subject to certain conditions, including receipt of regulatory and stock exchange approvals and approval from a 66 2/3% majority of the votes cast by Labrador Gold shareholders at a special meeting to be scheduled in early July 2024. Directors, officers, and certain shareholders of Labrador Gold have entered into voting support agreements with NFG and have agreed to vote their shares in favor of the transaction. According to the company’s corporate presentation, insiders own approximately 13.2% of Labrador’s outstanding shares and institutional investors own 23.0%.  


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Energy Fuels (UUUU) – Energy Fuels to acquire Base Resources and shore up Rare Earth Element supply

Posted on by cpereira@noblefcm.com


Tuesday, April 23, 2024

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. Energy Fuels also produces vanadium from certain of its projects, as market conditions warrant, and is ramping up commercial-scale production of REE carbonate. Its corporate offices are in Lakewood, Colorado, near Denver, and all its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant, as well as REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is www.energyfuels.com.

Michael Heim, Senior Vice President, Equity Research Analyst, Energy & Transportation, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Energy Fuels agreed to acquire Base Resources (ASX: BSE) for $242 million. Payment would consist of 0.0260 shares of UUUU stock and $0.042 in cash for each BSE share. UUUU management believes the acquisition will be immediately accretive and significantly add to Energy Fuel’s value given BSE assets with a PV10 estimated value close to $2 billion.

BSE’s Toliara project in Madagascar is the key to the purchase. Toliara is a world-class, advanced-stage, low-cost, and large-scale heavy sands project with large quantities of Monazite sand. The monazite will be shipped to UUUU’s White Mesa Mill for processing. Along with other monazite projects (Chemours, Donald, Bahia) Energy Fuels will now have enough monazite to proceed with the mill’s phase II expansion, which will increase capacity 5-6 times and begin separating heavy REEs. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

AZZ Inc. (AZZ) – Fiscal 2024 4Q and year results meet expectations

Posted on by cpereira@noblefcm.com


Tuesday, April 23, 2024

Michael Heim, Senior Vice President, Equity Research Analyst, Energy & Transportation, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Seasonal decline was less due to warm weather. Precoat Metals reported strong results as construction sale benefitted from warm weather. Appliance sales were also strong.

Margins continue to improve steadily as increased sales are spread over fixed costs. Consolidated margins dipped slightly with the shift towards lower-margin Precoat Metal sales, but the overall trend continues to rise.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Home Collectible Brand Longaberger Weaves Two Iconic American Brands Together With Its Newest Crayola Collaboration

Posted on by aweinsoff@channelchek.com

Research News and Market Data on XELB

April 22, 2024 at 10:00 AM EDT

PDF Version

Longaberger x Crayola Home Accessories Collection to exclusively launch on Longaberger.com

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) — Longaberger and Crayola are excited to introduce a new partnership and the launch of their home accessory collection. The collection features vibrant, fun designs that embody the spirit of creativity. This collection will launch exclusively on Longaberger.com.

Tailored for spring and year-round happiness, this new collection introduces four captivating baskets in multiple colorways. Elevating our basket designs through creative expression creates a selection perfect for collectors—Crayola and Longaberger lovers alike. Each basket features distinct Crayola characteristics, iconic Crayola colors, and hand-woven craftmanship.

“We are thrilled to see this partnership come to life with the first Longaberger x Crayola Collection. This collaboration will inspire creativity, promote self-expression, and bring color, the greatest luxury, into your home,” shared Joe Falco, President, Chief Merchandising Officer of Xcel Brands. 

“Crayola is known for inspiring creativity through color. This collaboration combines Longaberger’s signature style and design with Crayola’s iconic shape and colors for a collection that is imaginative, one of a kind, joyful,” said April Heeren, General Manager, Crayola Outbound Licensing.

Longaberger has been transforming houses into homes since 1896, providing both functionality and beauty to its customers. This partnership highlights the colorful elements of Crayola with the history of Longaberger. Together, we are fostering a creative connection in an innovative but familiar way. These baskets are the perfect vessels to bring color into your home, and inspire creativity, fun and self-expression.

About Longaberger
Longaberger, founded by Dave Longaberger in 1973, is an American home collectibles brand known for artisanal handcrafted products. For generations, Longaberger has manufactured handmade maple baskets and home products that are collected by a loyal community of customers. In 2019, Xcel Brands acquired The Longaberger Company and launched with a new digital social selling business model, offering timeless and modern décor products that inspire a highly engaged community. To join the Longaberger Family as a Home & Life Stylist Influencer, visit longaberger.com/join and for more company information, visit the website at longaberger.com or on social media at @longaberger, #longaberger and #thelongabergerfamily.

About Xcel Brands

Xcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, marketing, live streaming, social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as one thing. Xcel owns the Judith Ripka, Halston, LOGO by Lori Goldstein, and C. Wonder by Christian Siriano brands and a minority stake in the Isaac Mizrahi brand. It also owns and manages the Longaberger brand through its controlling interest in Longaberger Licensing LLC and a 50% interest in a JV in TWRHLL (“Tower Hill”) by Christie Brinkley. Also, Xcel owns a 30% interest in Orme, a short-form video marketplace. Xcel is pioneering a true modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retail, and e-commerce channels to be everywhere its customer’s shop. The company’s brands have generated in excess of $4 billion in retail sales via livestreaming in interactive television and digital channels alone. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. www.xcelbrands.com.

About Crayola
Crayola LLC, based in Easton, Pa. and a business of Hallmark Cards, Inc., is the worldwide leader in children’s creative expression products. Known for the iconic Crayola Crayon first introduced in 1903, the Crayola brand has grown into a portfolio of innovative art tools, crafting activities, and creativity toys that offer children innovative new ways to use color to create everything imaginable. Consumers can find the wide array of Crayola products in the “Crayola Aisle” at all major retailers. For more information, visit www. crayola.com or join the community at www.facebook.com/crayola.

MEDIA CONTACT:
Marina Sacramone
Marketing & Social Media Director at Xcel Brands
msacramone@xcelbrands.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4c286bb8-a7f4-4a55-b7be-224c448336c5

Source: Xcel Brands, Inc